Sihuan Pharmaceutical Holdings Group First Half 2025 Earnings: EPS: CN¥0.011 (vs CN¥0.004 loss in 1H 2024)

Simply Wall St · 09/18/2025 23:13

Sihuan Pharmaceutical Holdings Group (HKG:460) First Half 2025 Results

Key Financial Results

  • Revenue: CN¥1.15b (up 21% from 1H 2024).
  • Net income: CN¥102.6m (up from CN¥33.4m loss in 1H 2024).
  • Profit margin: 9.0% (up from net loss in 1H 2024). The move to profitability was driven by higher revenue.
  • EPS: CN¥0.011 (up from CN¥0.004 loss in 1H 2024).
earnings-and-revenue-growth
SEHK:460 Earnings and Revenue Growth September 18th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sihuan Pharmaceutical Holdings Group Earnings Insights

Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are down 3.0% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Sihuan Pharmaceutical Holdings Group's balance sheet health.